Current trials open at Baptist Cancer Network:
A191901 (GET SET)-Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (GET SET stands for Guiding Endocrine Therapy Success through Empowerment and Technology): Research opportunity for women who take medicine to help keep breast cancer from coming back. The medicines are endocrine therapies and include Tamoxifen or Arimidex. Women enrolled in this study will receive either text message motivation, counselor motivation, text and counselor motivation, or standard of care.
SER-ISD1-001-A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss. This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
NEAAR-001-Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer. This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.
Boston II Study-Diagnostic performance of small RNA blood test in patients undergoing follow-up imaging after positive low dose CT screening for cancer of the lung “Early Detection of Lung Cancer based on small RNA signatures – Boston II”. The study is a prospective, longitudinal, observational study to evaluate the performance of a novel diagnostic test for early-stage lung cancer. Study duration: Expected patient enrollment to be completed within 12 months after study initiation. Patients will be followed for a minimum of 12 months from the date of enrollment. The study duration is approximately 2 years. Participant duration: The day of blood collection. Participants will follow their regular standard of care schedule as recommended by existing guidelines; no extra visits are planned. Follow up data will be obtained from the electronic medical record within at least 12 months of follow-up period.
ICARE-Registry-Inherited CAncer REgistry (ICARE) Initiative: Registry opportunity through Vanderbilt-Ingram Cancer Center for individuals with a personal and/or family history of cancer.
To learn more about these studies, you can find the protocols at https://clinicaltrials.gov/ or you may contact Research Coordinator Telice Terro at 409-212-5979 or telice.terro@bhset.net